Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 8
Submit an article Journal homepage
146
Views
49
CrossRef citations to date
0
Altmetric
Miscellaneous

Efflux in bacteria: what do we really know about it?

Brenda M Ryan
,
Thomas J Dougherty
,
Danielle Beaulieu
,
Julia Chuang
,
Brian A Dougherty
&
John F Barrett
Pages 1409-1422 | Published online: 24 Feb 2005

Bibliography

  • BORGES-WALMSLEY MI, WALMSLEY AR: The structure and function of drug pumps. Trends Nlicrobial. (2001) 9(2):71–79.
  • •Excellent review of the biology and biochemistry of drug pumps.
  • LEWIS K, HOOPER DC, OUELLETTE M: Multidrug resistance pumps provide broad defense. ASM News (1997) 11:605–610.
  • LEWIS K: Multidrug resistance: Versatile drug sensors of bacterial cells. Curr. Biol. (1999) 9:R403–407.
  • •Excellent review on the diversity and wide breadth of versatility of bacterial efflux pumps.
  • VAN VEEN HW, KONIGS WN: Structure and function of multidrug transporters. In: Resolving the Antibiotic Paradox (Ed. Rosen and Mobashery), 1998. Kluwer Academic/ Plenum Publish, NY, USA.
  • PAULSEN IT, BROWN MH, SKURRAY RA: Proton-dependent multidrug efflux systems. ll/licrobial Rev (1996) 60:575–608.
  • SAIER MH, PAULSEN IT, SLIWINSKI MK, PAO SS, SKURRAY RA, NIKAIDO H: Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J. (1998) 12:265–274.
  • •Provocative review on the origins of bacterial efflux pumps.
  • SHAROM FJ: The P-glycoprotein efflux pump: How does it transport drugs? J. Meath. Biol. (1997) 160(3):161–175.
  • VAN BAMBEKE E BALZI E, TULKENS PM: Antibiotic efflux pumps. Biochem. Phann. (2000) 60:457–470.
  • •Excellent overview of bacterial antibiotic efflux pumps.
  • HIGGENS CF: ABC transporters: From microorganisms to man. Ann. Rev Cell Biol. (1992) 8:67–113.
  • LAWRENCE LE, BARRETT JF: Overview, clinical relevance, and potential pharmaceutical target. Expert Opin Investig. Drugs (1998) 7(2):199–217.
  • •Practical application of efflux pump research as applied to pharmaceutical intervention.
  • SAIER MH, PAULSEN IT, MATIN A: A bacterial model system for understanding multi-drug resistance. ll/licrob. Drug Resist. (1997) 3(4):289–295.
  • NIKAIDO H: Antibiotic resistance caused by gram-negative multidrug efflux pumps. Biochem. Mech. (1998) 27\(Suppl. 1):S32–41.
  • ZGURSKAYA HI, NIKAIDO H: Multidrug resistance mechanisms: drug efflux across two membranes. Ma 11/licrobiol. (2000) 37(2):219–225.
  • SUTCLIFFE J: Resistance to macrolide mediated by efflux mechanisms. Curr. Opin. Anti-Infect. Invest. Drugs (1999) 1(4):403–412.
  • BROWN MH, PAULSEN IT, SKURRAY RA: The multidrug efflux protein NorM is a prototype of a new family of transporters. Mal Microbial (1999) 31(1):394–395.
  • LEE A, MAO W, WARREN MS et al.: Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J. Bacterial. (2000) 182:3142–3150.
  • NEYFAKH AA: The ostensible paradox of multidrug recognition. J. Mal ll/licrobial Biatechnol (2001) 3(2):151–154.
  • PAN W, SPRATT BG: Regulation of thepermeability of the gonococcal cell envelope by the mtr system. Mal Microbial (1994) 11(4):769–775.
  • SMITH TF, WATERMAN MS, FITCH WM: Comparative biosequence metrics. J. Mal Eva]. (1981) 18(1):38–46.
  • ALTSCHUL SF, GISH W, MILLER W et al.: Basic local alignment search tool. I Ma Biol. (1990) 215(3):403–410.
  • PEARSON WR, LIPMAN DJ: Improved tools for biological sequence comparison. Proc. Natl. Acad. Li. USA (1988) 85(8):24444–24448.
  • HIGGINS DG, SHARP PM: CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene (1988) 73(1):237–244.
  • EDDY SR: Hidden Markov models. Curr. Opin. Struct. Biol. (1996) 6(3):361–365.
  • PAULSEN IT, CHEN J, NELSON KE et al.: Comparative genomics of microbial drug efflux systems. j Mol. 11/licrobial. Biatechnol. (2001) 3(2):145–150.
  • •Excellent analyses of potential efflux pumps in bacteria based on genomics data.
  • NELSON KE, PAULSEN IT, HEIDELBERG JF etal.: Status of genome projects for nonpathogenic bacteria and archaea. Nat. Biatechnol. (2000) 18(10):1049–1054.
  • KARP PD, RILEY M, SAIER M, PAULSEN IT, PALEY SM, PELLEGRINI-TOOLE A: The ecoCyc and MetaCyc databases. Nuc. Acids Res. (2000) 28(1):56–59.
  • DAVIS DR, MCALPINE JB, PAZOLES CJ et al.: Enterocaccus faecalis multi-drug resistance transporters: application for antibiotic discovery. I Mal Microbial Biatechnol. (2001) 3(2):179–184.
  • NEYFAKH AA: Natural functions of bacterial multidrug transporters. Trends Microbial (1997) 5(8):309–313.
  • •Excellent review on the 'natural' functions of bacterial efflux pumps.
  • LEWIS K: Multidrug resistance efflux. In:Transport of Molecules across Microbial Membranes. Broome-Smith JK, Baumberg S, Stirling CJ, Ward FB (Eds.), Cambridge University Press, Cambridge, UK (1999):15–40.
  • VAN VEEN HW, KONINGS WN: Drug efflux proteins in multidrug resistant bacteria. Biol. Chem. (1997) 378:769–777.
  • VAN VEEN HW, PUTMAN M, MARGOLLES A, SAKAMOTO K, KONINGS WN: Molecular pharmacological characterization of two multidrug transporters in Lactococcus lactis. Pharmac. Ther (2000) 85:245–249.
  • EDGAR R, BIBI E: MdfA, an Escherichia colimulddrug resistance protein with an extraordinary broad spectrum of drug recognition. I Bacterial. (1997) 179(7)2274–2280.
  • MATA MT, BAQUERO E PEREZ-DIAZ JC: A multidrug efflux transporter in Listeria mortacytagenes. FEMS Micro. Lett. (2000) 187:185–188.
  • JENKINSON HF: Ins and outs of antimicrobial resistance era of the drug pumps. J. Dent. Res. (1996) 75(2):736–742.
  • SCHMITZ FJ, FLUIT AC, BRISSE S, VERHOEF J, KOHRER K, MILATOVIC D: Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immun. Med. Mau (1999) 26:281–287.
  • •Practical review of relevance of efflux in terms of clinical isolate susceptibilites.
  • GILL MJ, BRENWALD NP, WISE R: Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus prieumardae. Antimicrob. Agents Chemother. (1999) 43(1):187–189.
  • ROSENBERG EY, MAD, NIKAIDO H: AcrD of Echerichia coil is an aminoglycoside efflux pump. I Bacterial (2000) 182(6):1754–1756.
  • RAMOS AIRES J, KOHLER T, NIKAIDO H, PLESIAT P: Involvement of an active efflux system in the natural resistance of Pseudamortas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. (1999) 43(11):2624–2628.
  • PAULSEN IT, SKURRAY RA, TAM R et al.: The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mal Microbial (1996) 19(6):1167–1175.
  • JACK DL, STORMS ML, TCHIEU JH, PAULSEN IT, SAIER JR MH: A broad-specificity multidrug efflux pump requiring a pair of homologous SMR-type proteins. Bacterial (2000) 182(8):2311–2313.
  • POELARENDS GJ, MAZURKIEWICZ P, PUTMAN M, COOL RH, VAN VEEN HW, KONINGS WN: An ABC-type multidrug transporters of Lactococcus lactis possesses an exceptionally broad substrate specificity. Drug Resist. Updates. (2000) 3:330–334.
  • ALLIGNET J, EL SOLH N: Characterization of a new staphylococcal gene, VgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. Gene (1997) 202:133–138.
  • WESTBROOK-WADMAN S, SHERMAN DR, HICKEY MJ etal.: Characterization of a Pseudamortas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob. Agents Chemother. (1999) 43(12):2975–2983.
  • NAKAE T, NAKAJIMA A, ONO T, SAITO K, YONEYAMA H: Resistance to P-Lactam antibiotics in Pseudamortas aeruginosa due to interplay between the MeicAB-OprM efflux pump andl3-Lactamase. Antimicrob. Agents Chemother. (1999) 43(5):1301–1303.
  • POOLE K: Efflux-mediated resistance to fluoroquinolone in gram-positive bacteria and the mycobacteria. Antimicrob. Agents Chemother (2000) 44(10):2595–2599.
  • GUERIN F, VARON E, BUU HOI A, GUTMANN L, PDOGLAJEN I: Fluoroguinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob. Agents Chemother (2000) 44(8):2197–2200.
  • ZHONG P, SHORTRIDGE VD: The role of efflux in macrolide resistance. Drug Resist. Updates (2000) 3:325–329.
  • ZIHA-ZARIFI I, LLANES C, KOHLER T, PECHERE JC, PLESIAT P: In vivo emergence of multidrug -resistant mutants of Pseudamorms aeruginosa overexpressing the active efflux system MeicA-MexB-OprM. Antimicrob. Agents Chemother. (1999) 43(2):287–291.
  • GHOSH AS, AHAMED J, CHAUHAN KK, KUNDU M: Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem. Biophys. Res. Comm. (1998) 242:54–56.
  • DRUG UPDATES #1 - IMS World (2001)2000:278, RN233686-67–4.
  • RENAU TE, LEGER R, LAMME EM et al.: Inhibitors of efflux pumps in Pseudamortas aeruginosa potentiate the activity of the fluoroquinolone antibacterial Levofloxacin. I Med. Chem. (1999) 42(24):4928–4931.
  • NELSON ML, PARK BH, ANDREWS JS, GEORGIAN VA, THOMAS RC, LEVY SB: Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines. I Med. Chem. (1993) 36(3): 370–377.
  • MARKHAM PN, WESTHAUS E, KLYACHKO K, JOHNSON ME, NEYFAKH AA: Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. (1999) 43(10):2404–2408.
  • LEE A, LOMOVSKAYA 0: Deletion of efflux pumps affects the emergence of resistance to Levofloxacin in P aeruginosa. Interscience Conference On Antimicrobial Agents in Chemotherapy San Diego, CA, USA (1998) C–119.
  • LOMOVSKAYA 0, LEE A, MISTRY A et al.: Multidrug resistance pumps as important targets in antibacterial therapy. Interscience Conference On Antimicrobial Agents in Chemotherapy San Diego, CA, USA (1998) C–1120.
  • LOMOVSKAYA 0, LEE A, HOSHINO K et al.: Use of genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudamorras aerugirrosa. Antimicrob. Agents Chemother. (1999) 43(6):1340–1346.
  • LEE A, MAO W, WARREN M et al: Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance.j Bacterial (2000) 182(11):3142–3150.
  • •Study of the relevance of efflux pumps in bacterial drug resistance.
  • LOMOVSKAYA 0, HOSHINO K, ISHIDA H et al: Identification and characterization of efflux pump inhibitors in 1? aerugirrosa. Interscience Conference on Antimicrobial Agents in Chemotherapy San Francisco, CA, (1999) F1264.
  • LOMOVSKAYA 0, WARREN M, LEE A et al: Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudamorras aerugirrosa: Novel agents for combination therapy. Antimicrob. Agents Chemother. (2001) 45(1):105–116.
  • •Proof-of-principle in vitro study of application of efflux pumps in reversing resistance.
  • INVESTIGATIONAL DRUGS DATABASE. Drug report for MC-207,110, 2000:1527, update March 7, (2001).
  • ADIS R&D INSIGHTS - MC-207,110: Last update 2000-12-28, accession number 12726.
  • BLAIS J, CHO D, TANGEN K et al: Efflux pumps inhibitors (EPIs) enhance the activity of antimicrobial agents against a broad selection of bacteria. Interscience C017felE17Ce On Antimicrobial Agents in Chemotherapy San Francisco, CA, USA (1999) F–1266.
  • GRIFFITH D, LOMOVSKAYA 0, LEE V, DUDLEY M: Potentiation of levofloxacin (levo) by a broad-spectrum efflux pump inhibitor (EPI) in mouse models of infection due to Pseudamorras aerugirrosa. Interscience Conference on Antimicrobial Agents in Chemotherapy San Francisco, CA, USA (1999) F–1268.
  • WARREN MS, LEE JC, LEE A, HOSHINO K, ISHIDA H, LOMOVSKAYA 0: An inhibitor of the Mex pumps from Pseudamorras aerugirrosa is also a substrate of these pumps. Interscience Conference on Antimicrobial Agents in Chemotherapy Toronto, Canada (2000) 1495.
  • ADIS R&D INSIGHTS record on MC 002434. Update 2000-12-28. Accession number 13735.
  • RENAU T, LEGER R, GANNON CL, MATHIAS KM et al.: Addressing the stability of c-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudamorras aerugirrosa. Interscience Conference on Antimicrobial Agents in Chemotherapy. Toronto, Canada (2000) 1493.
  • ADIS R&D INSIGHTS record on MC 02595. Update 2000-09-26. Accession number 14646.
  • GRIFFITH D, LOMOVSKAYA 0, LEE VJ, DUDLEY M: Potentiation of levofloxacin by MC-02,595, a broad spectrum efflux pump inhibitor in mouse models of infection due to Pseudamorras aerugirrosa with combinations of different Mex pump expression and gyrA mutation. Interscience Conference on Antimicrobial Agents in Chemotherapy. Toronto, Canada (2000) 1496.
  • LEGER R, RENAU TE, ZHANG JZ et al:Peptidomimetics of dipeptide amide efflux pump inhibitors potentiate the activity of levofloxacin in Pseudamorras aerugirrosa. Interscience Conference on Antimicrobial Agents in Chemotherapy. Toronto, Canada (2000) 1494.
  • ADIS R&D INSIGHTS record on MC 04124. Update 2000-09-26. Accession number 14647.
  • BARRETT JF: ICAAC 40th meeting (Part XII), Toronto Canada. Investigational Drug Database Meeting report. Feb 28, (2001).
  • CHO D, LOFLAND D, BLAIS J et al: Anefflux pump inhibitor MC-04,124, enhances the activity of macrolides against gram negative bacteria. Interscience Conference on Antimicrobial Agents in Chemotherapy Toronto, Canada (2000) 1497.
  • LEE JC, GALAZZO JL, CANIRO T et al:MF-GA-372 and MF-GA-371 S novel bacterial efflux pump inhibitors from microbial fermentation. Interscience Conference on Antimicrobial Agents in Chemotherapy Toronto Canada (2000) 1499.
  • ADIS R&D INSIGHTS record on MC-510051. Update 2000-12-28. Accession number 14689.
  • ADIS R&D INSIGHTS, record on Research Programme: antibacterials - GlaxoSmithKline/Paratek Pharmaceuticals. Update 2001-01-23. Accession number 12401.
  • NELSON ML, LEVY SB: Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob. Agents Chemother. (1999) 43(7):1719–1724.
  • ADIS R&D INSIGHTS, report on UK57562. Update 2000-06-03. Accession number 12728.
  • RYDER NS: ICAAC 39th meeting (Part X),San Fransisco, CA. Investigational Drug Database Meeting report. (July 2000).
  • GUZ NR, STERMITZ FR, JOHNSON JB et al.: Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: structure-activity relationship. I Med. Chem. (2001) 44(2):261–268.

Websites

  • http://www.biology.ucsd.edu/- ipaulsen/ transport
  • http://www.Tignorghdb/mdb/ mdbcomplete.html
  • http://witintegratedgeno-mics.comi GOLD/completegenomes.html
  • http://www-biology.ucsd.msaiedtransportititlepage 2.html
  • http://ecocyc.PangeaSystems.corniecocyci Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.